Impact of Combination Antibiogram and Related Education on Inpatient Fluoroquinolone Prescribing Patterns for Patients With Health Care–Associated Pneumonia
暂无分享,去创建一个
Baoqi Liang | James S Wheeler | Lisa M Blanchette | James S. Wheeler | Lisa M. Blanchette | Baoqi Liang
[1] C. Gentry,et al. Outcomes of Health Care–Associated Pneumonia Empirically Treated with Guideline-Concordant Regimens Versus Community-Acquired Pneumonia Guideline–Concordant Regimens for Patients Admitted to Acute Care Wards from Home , 2013, The Annals of pharmacotherapy.
[2] D. Chung,et al. Community-acquired pneumonia requiring hospitalization among U . S . adults , 2016 .
[3] 古谷 良輔,et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.
[4] Daniel J Sexton,et al. Health CareAssociated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired Infections , 2002, Annals of Internal Medicine.
[5] L. Leibovici,et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. , 2004, BMJ.
[6] Marin H Kollef,et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. , 2005, Chest.
[7] L. Lanthier,et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] W. Scheld,et al. Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors , 2003, Emerging infectious diseases.
[9] S. Weber,et al. Optimizing Empirical Antimicrobial Therapy for Infection due to Gram-Negative Pathogens in the Intensive Care Unit: Utility of a Combination Antibiogram , 2010, Infection Control & Hospital Epidemiology.
[10] T. V. Van Schooneveld,et al. Epidemiology and Predictors of Multidrug-Resistant Community-Acquired and Health Care-Associated Pneumonia , 2014, Antimicrobial Agents and Chemotherapy.
[11] M. Niederman,et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] H. Saka,et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. , 2013, American journal of respiratory and critical care medicine.
[13] M. Kollef,et al. A comparison of culture-positive and culture-negative health-care-associated pneumonia. , 2010, Chest.
[14] J. Quinn,et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. , 2003, JAMA.
[15] Leonard Leibovici,et al. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.
[16] M. Niederman,et al. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia , 2009, Current opinion in infectious diseases.
[17] D. Gerding. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] S. Ewig,et al. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] M. Weiner,et al. Identification of Optimal Combinations for Empirical Dual Antimicrobial Therapy of Pseudomonas aeruginosa Infection: Potential Role of a Combination Antibiogram , 2006, Infection Control & Hospital Epidemiology.
[20] M. Kollef,et al. Health Care-Associated Pneumonia and Community-Acquired Pneumonia: a Single-Center Experience , 2007, Antimicrobial Agents and Chemotherapy.
[21] N. Boyd,et al. Combination Antibiotic Therapy for Empiric and Definitive Treatment of Gram‐Negative Infections: Insights from the Society of Infectious Diseases Pharmacists , 2011, Pharmacotherapy.